SC134-deruxtecan a fucosyl-GM1 targeting ADC for small cell lung cancer therapy

Background Small cell lung cancer (SCLC) remains a difficult disease to treat with poor long-term survival rates. New therapies offer modest overall survival benefit beyond that of chemotherapy alone, necessitating the development of improved therapies. Fucosyl-GM1 (FucGM1) is a glycolipid highly expressed on SCLC cells, but virtually absent in normal tissues, suggesting strong potential for targeted therapy. We have developed SC134-deruxtecan, an antibody drug conjugate (ADC) targeting FucGM1 in SCLC, and characterized its preclinical activity. Methods SC134 binding specificity and affinity were tested through enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), flow cytometry against several SCLC cell lines, and immunohistochemistry (IHC) of clinical samples and animal tissues. In silico modelling supplemented the FucGM1 binding specificity. Internalization kinetics and colocalization of SC134 with the lysosomes were investigated through imaging flow cytometry. Direct cytotoxicity as well as bystander killing and antibody dependent cell cytotoxicity (ADCC) by SC134-deruxtecan were determined using in vitro cell cytotoxicity assays. SC134-deruxtecan’s efficacy was evaluated in vivo using a DMS79 xenograft model. Results SC134 specifically targets FucGM1, without GM1 cross-reactivity, with nanomolar affinity. In silico modelling of the SC134 FucGM1 binding site revealed a relatively narrow binding pocket, occupied by the terminal three glycans with multiple Fucose-engaging interactions. Robust FucGM1 expression in frozen SCLC patient tissues was evident, whilst tissue cross-reactivity analysis indicated non-human primates as well as mice as suitable toxicology models. FucGM1 binding by SC134 led to effective internalization, with a 6.9-hour half-life, lysosomal colocalization, culminating in sub-nanomolar efficiency drug delivery, across a range of payloads. Covalent deruxtecan conjugation of SC134 with a DAR8 and a cleavable linker showed effective (nanomolar) in vitro killing of SCLC cell lines such as DMS79 and DMS153, with concentration-dependent bystander killing of FucGM1-negative AGS cells. SCLC cell killing was further augmented through ADCC. Potent in vivo DMS79 xenograft killing was seen at 3mg/kg SC134-deruxtecan, which was well tolerated. Conclusions The tumour-specific nature of FucGM1, combined with the potent SCLC killing by SC134-deruxtecan underscore the development potential of SC134-deruxtecan for use as an ADC therapy against SCLC.